Individualized chemotherapy in advanced NSCLC patients based on mRNA levels of BRCA1 and RRM1
- 1 March 2012
- journal article
- Published by Chinese Journal of Cancer Research in Chinese Journal of Cancer Research
- Vol. 24 (3), 226-231
- https://doi.org/10.1007/s11670-012-0226-4
Abstract
Experimental evidence suggests that the overexpression of breast cancer-specific tumor suppressor protein 1 (BRCA1) gene enhances sensitivity to docetaxel and resistance to cisplatin and ribonucleotide reductase M1 (RRM1) gene overexpression enhances resistance to gemcitabine. To further examine the effect of BRCA1 and RRM1 mRNA levels on outcome in advanced non-small cell lung cancer (NSCLC), we performed this non-randomized phase II clinical trial which tested the hypothesis that customized therapy would confer improved outcome over noncustomized therapy. RNA was isolated from fresh tumor tissue. Patients received chemotherapy regimen based on their BRCA1 and RRM1 mRNA levels: both low-cisplatin plus gemcitabine (GP); both high-vinorelbine plus cisplatin (NP); BRCA1 low and RRM1 high-cisplatin plus docetaxel (TP); BRCA1 high and RRM1 low-vinorelbine plus gemcitabine (GN). From Dec 2005 to Nov 2008, 94 metastatic and locally advanced NSCLC patients from our institute were enrolled in this study. The median age was 58 years old. Among them, 21 patients received GP, 30 patients received TP and 43 patients received NP chemotherapy. GP group had a higher response rate, and longer median time to progression (TTP) and median overall survival (OS) time than the other 2 groups. The response rates in the GP, TP and NP groups were 42.9%, 36.7% and 27.9%, respectively (P=0.568). The median TTP was 5.6, 5.0, 4.8 months (P=0.975), respectively, and the median OS time was 12.5, 11.0, 9.7 months (P=0.808), respectively. Chemotherapy customized according to BRCA1 and RRM1 expression levels is associated with higher response rate and longer TTP and OS time in the GP group. This suggests that BRCA1 and RRM1 mRNA levels could be used as biomarkers in individual therapy in NSCLC.Keywords
This publication has 23 references indexed in Scilit:
- Cancer incidence and mortality in China, 2006Chinese Journal of Cancer Research, 2011
- High expression of ERCC1 is a poor prognostic factor in Chinese patients with non-small cell lung cancer receiving cisplatin-based therapyChinese Journal of Cancer Research, 2010
- High-Level mRNA of Excision Repair Cross-Complementation Group 1 Gene Is Associated With Poor Outcome of Platinum-Based Doublet Chemotherapy of Advanced Nonsmall Cell Lung Cancer PatientsCancer Investigation, 2010
- ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancerMedical Oncology, 2010
- Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancerLung Cancer, 2009
- Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapyLung Cancer, 2009
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysisJNCI Journal of the National Cancer Institute, 2007
- Gene Expression and Polymorphisms of DNA Repair Enzymes: Cancer Susceptibility and Response to ChemotherapyClinical Lung Cancer, 2007
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002